Exploring Subsets of Patients With Mantle Cell Lymphoma
Sonali M. Smith, MD, discusses the current understanding of mantle cell lymphoma and how this understanding has evolved over recent years to understand different subsets of the disease that may require different frontline treatment for patients.
Sonali M. Smith, MD, of the University of Chicago Medicine, discusses the current understanding of mantle cell lymphoma (MCL) and how this understanding has evolved over recent years to understand different subsets of the disease that may require different frontline treatment for patients.
The standard of care in the frontline setting of MCL generally depends on the amount of a disease the patient presents with, the patient’s age, and their overall fitness. However, we have come a long way in our understanding of MCL, says Smith. It was first described and thought to be an aggressive disease in all patients. However, some patients present with more indolent MCL with an indolent disease course.
Smith says subsets of MCL include nodal, small volume or those with a low tumor mutational burden, or leukemic. Leukemic presents similar to chronic lymphocytic leukemia.
Overall, it is important to pull these patients aside in the frontline, Smith says. These patients can often be safely observed for a while without receiving initial frontline therapy, which physicians refer to as the “watch and wait” approach.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
